ADULT MEDICATION GUIDELINE	
Promethazine	
Scope (Staff):	All WNHS Staff
Scope (Area):	Obstetrics and Gynaecology
This document should be read in conjunction with the Disclaimer.	

Quick Links

Dose	Administration	Monitoring	Pregnancy and Breastfeeding

Restrictions

Formulary: Restricted (Injection)

Formulary: Unrestricted

Medication Class

Sedating antihistamine

Presentation

Tablet: 10 mg; 25 mg

Ampoule: 50 mg/2 mL

Note: NOT for IV, IA or subcut administration. Promethazine is highly caustic and extravasation may cause pain, paralysis and necrosis.

Storage

Store at room temperature, below 25°C. Protect from light.

Dose

Nausea and vomiting

Oral or IM:

25 mg every 6 to 8 hours as required. Maximum 100 mg in 24 hours.

Allergy/Urticaria (*Not recommended in the treatment of anaphylaxis*)

Oral

25 mg to 75 mg once daily **OR**

10 mg to 25 mg 2 to 3 times a day. Maximum 100mg in 24 hours

IM:

25 mg to 50 mg as a single dose.

Sedation (short term)

Oral:

25 mg to 75 mg as a single dose.

For short-term use under medical supervision. Give 1–2 hours before procedure or as a single dose at night.

Administration

Oral *(preferred route)*

Take tablet with a glass of water. Can be crushed and dispersed in water if patient has swallowing difficulty.

IM

Inject deep into a large muscle.

Note: NOT for IV, IA or subcut administration. Promethazine is highly caustic and extravasation may cause pain, paralysis and necrosis.

Refer to the Australian Injectable Drugs Handbook

Monitoring

Sedation

Pregnancy

1st Trimester: Safe to use

2nd Trimester: Safe to use

3rd Trimester: Safe to use

For more information, please contact KEMH Obstetric Medicines Information Service.

Breastfeeding

Consider alternative

For more information, please contact KEMH Obstetric Medicines Information Service.

Related Policies, Procedures & Guidelines

WNHS Clinical Practice Guidelines:

Pregnancy care: First trimester complications

Neuraxial Analgesia

WNHS Pharmaceutical and Medicines Management Guidelines:

Medication Administration

References

Australian Medicines Handbook. Promethazine. In: Australian Medicines Handbook [Internet]. Adelaide (South Australia): Australian Medicines Handbook; 2025 [cited 2025 Mar 27]. Available from: https://amhonline.amh.net.au/

AusDI. Antihistamines, Phenothiazine-derivative (Systemic). In: AusDI [Internet]. Telstra Health: AusDI; [cited 2025 Mar 27]. Available from: Antihistamines, Phenothiazine-derivative (Systemic) - AusDI (health.wa.gov.au)

Therapeutic Guidelines. Oral antiemetics for nausea and vomiting during pregnancy. In: eTG complete [Internet]. West Melbourne (Victoria): Therapeutic Guidelines; 2022 [cited 2025 Mar 27]. Available from: https://tgldcdp-tg-org-au.kelibresources.health.wa.gov.au/etgAccess

The Royal Women's Hospital. Promethazine. In: Pregnancy and Breastfeeding Medicines Guide [Internet]. Parkville (Victoria): The Royal Women's Hospital; 2024 [cited 2025 Mar 27]. Available from: https://thewomenspbmg.org.au/

Society of Hospital Pharmacists of Australia. Promethazine In: Australian Injectable Drugs Handbook [Internet]. [St Leonards, New South Wales]: Health Communication Network; 2025 [cited 2025 Mar 27]. Available from: https://aidh-hcn-com-au.

Society of Obstetric Medicine of Australia and New Zealand. OMANZ Position Statement for Management of Nausea and Vomiting of Pregnancy and Hyperemesis Gravidarum [Internet]. Sydney (New South Wales): SOMANZ; 2023 [cited 2025 Mar 27]. Available from: https://somanz.org/content/uploads/2023/12/SOMANZ-Management-of-NVP-Position-Statement-Updated-Oct-2023-FINAL-1.pdf

Keywords	Promethazine; phenergan; allersoothe; sedating antihistamine; sedation; nausea and vomiting; allergy; itch; urticaria				
Document Owner:	Chief Pharmacist				
Author/ Reviewer	KEMH Pharmacy Department				
Version Info:	5.0				
Date First Issued:	May 2015	Last Reviewed:	April 2025	Review Date:	April 2030
Endorsed by:	Medicines and Therapeutics Committee			Date:	03/06/2025
NSQHS Standards Applicable:	☒ Std 1: Clinical Governance ☐ Std 2: Partnering with Consumers ☐ Std 3: Preventing and Controlling Healthcare Associated Infection ☒ Std 4: Medication Safety			☐ Std 5: Comprehensive Care ☐ Std 6: Communicating for Safety ☐ Std 7: Blood Management ☐ Std 8: Recognising and Responding to Acute Deterioration	
Printed or personally saved electronic copies of this document are considered uncontrolled. Access the current version from WNHS HealthPoint.					

This document can be made available in alternative formats on request for a person with a disability.

© Women and Newborn Health Service 2025

Copyright of this material is vested in the State of Western Australia unless otherwise indicated. Apart from any fair dealing for the purposes of private study, research, criticism or review, as permitted under the provisions of the Copyright Act 1968, no part may be reproduced or re-used for any purposes whatsoever without written permission of the State of Western Australia.